决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.
这些发现共同确定,铁驱动的铁死亡是 CAR-T 细胞功能障碍的决定因素,也是阻碍 CAR-T 获得持久疗效的可靶向屏障。
嵌合抗原受体(CAR)T细胞的长期持久性对于实现持久疗效至关重要,但其功能障碍的机制尚不清楚。基于多发性骨髓瘤和急性淋巴细胞白血病CAR-T治疗参与者临床样本的整合分析,我们发现CAR-T细胞输注后快速扩增,随后进入“衰减”阶段,其特征为出现铁死亡相关特征及血清铁水平升高。在雌性小鼠临床前癌症模型和离体培养系统中,细胞内铁过量会损害CAR-T功能。从机制上看,铁可通过增加线粒体活性氧及脂质过氧化促进铁死亡,部分过程涉及长链脂酰辅酶A合成酶4(ACSL4)相关脂质重塑。靶向铁死亡,特别是通过在CAR-T细胞中遗传敲除ACSL4,可显著增强抗肿瘤疗效。综上,本研究确定铁驱动的铁死亡是CAR-T细胞功能障碍的决定因素,也是阻碍CAR-T持久疗效的可靶向屏障。
Long-term persistence of chimeric antigen receptor (CAR)-T cells is essential for durable therapeutic efficacy but the mechanisms underlying CAR-T cell dysfunction remain unclear. On the basis of integrated analyses of clinical samples from participants with multiple myeloma and acute lymphoblastic leukemia treated with CAR-T cells, we show that rapid expansion of CAR-T cells after infusion is followed by a 'diminution' phase characterized by ferroptosis-associated features and elevated serum iron levels. In preclinical cancer models in female mice and ex vivo culture systems, excess intracellular iron impaired CAR-T cell function. Mechanistically, iron promoted ferroptosis by increasing mitochondrial reactive oxygen species and lipid peroxidation, in part through acyl-CoA synthetase long-chain family member 4 (ACSL4)-associated lipid remodeling. Targeting ferroptosis, particularly through genetic ablation of ACSL4 in CAR-T cells, substantially enhanced antitumor efficacy. Together, these findings identify iron-driven ferroptosis as a determinant of CAR-T cell dysfunction and a targetable barrier to durable CAR-T efficacy.
MEMBER ACCOUNT
登录成功会直接打开下一页。